Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Recursion Pharmaceuticals director Christopher Gibson converted 20,000 shares of Class B Common Stock into 20,000 shares of Class A Common Stock on March 9, 2026. The conversion price was reported as $0.00 per share.
On the same date, he made a bona fide gift of 20,000 Class A shares, leaving him with 906,556 Class A shares directly owned and 4,523,334 Class B shares directly owned after these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
20,000 shares exercised/converted
Mixed
12 txns
Insider
Gibson Christopher
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 20,000 | $0.00 | -- |
| Conversion | Class A Common Stock | 20,000 | $0.00 | -- |
| Gift | Class A Common Stock | 20,000 | $0.00 | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Class B Common Stock — 4,523,334 shares (Direct);
Class A Common Stock — 926,556 shares (Direct);
Class B Common Stock — 0 shares (Indirect, by LAHWRAN-3 LLC);
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
- Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
FAQ
What insider transactions did Christopher Gibson report for RXRX?
Christopher Gibson reported converting 20,000 Class B shares into 20,000 Class A shares, then gifting 20,000 Class A shares. These moves changed only the mix and ownership of his holdings, without any open-market buying or selling activity.
What does the Class B to Class A conversion mean for RXRX’s insider structure?
Gibson’s conversion of 20,000 Class B shares into 20,000 Class A shares simply changes the class of part of his stake. Footnotes state each Class B share is convertible into one Class A share at the holder’s option and has no expiration date.
Were any Recursion (RXRX) derivative or option positions affected in this Form 4?
The reported conversion involved Class B shares that are themselves convertible into Class A shares. The filing also lists stock options with exercise prices between $2.48 and $11.40 and expirations from 2030 to 2035, indicating additional potential future Class A exposure.